Have you wondered about the role of patient engagement in healthcare product development?
Currently, there is a huge emphasis on the importance of using patient experience, preferences and insights. All this in an effort to inform the decision-making process of regulatory authorities and payers.
The Future of Patient Engagement
Both the EMA (European Medicines Agency) and the FDA (Food & Drug Administration) recognize the importance of the patients’ voice in their daily work. Additionally, they are urging healthcare product developers to integrate patient input in their development program.
In a similar way, the EUnet HTA is also committed to involving patients and their representatives in early dialogue. For instance, initiatives include parallel consultation, to capture as early as possible the perspectives on benefit in quality of life and patient reported outcomes.
However, there is still room for industry improvements to optimize collaborations. These should occur along the product development journey, by treating patients as partners.
Patient Engagement Questions Answered
Consequently, this webinar addresses patient engagement from three perspectives: a patient, patient association and industry:
- What are the real benefits & advances seen in patient engagement? For example, regulatory matters, disease awareness, issues around credibility, information dissemination, health equity, health literacy, etc.
- Are the specific barriers or limitations encountered?
- How the collaboration between industry and patients can be improved？
Three Different Perspectives
Hear directly from key stakeholders and experts…
A Patient Association
Firstly, hear from Kathy Oliver, Chair and founding Co-director of the International Brain Tumor Alliance, is a passionate advocate for equal access to new brain therapies worldwide. Moreover, she is highly active on matters of neuro-oncology and rare cancer, and she participates in numerous international committees.
An Industry Member
Secondly, Daniel De Schryver, who is patient engagement and advocacy lead for the EMEA region of the Janssen Pharmaceutical Companies of Johnson & Johnson. His focus has been to continuously improve the company’s relationship with the patient community, while engaging with patients and caregivers to build long-term partnerships and provide better solutions to challenges encountered.
Finally, Nadine Grossmann, who is a Ph.D. candidate at Freie Berlin University, who is motivated by personal reasons to advocate and raise awareness about rare disease. Furthermore, she is a board member of 2 patient organizations and is passionate about educating both health care experts and the general public.
Find out more on our unique patient engagement expertise in healthcare product development.